Merit Medical Systems, Inc. announced it has acquired View Point Medical, manufacture of the OneMark Detection Imaging System and OneMark Tissue Markers, for $140 million, according to a company press release.
“This acquisition expands Merit’s portfolio of therapeutic oncology products dedicated to the accurate diagnosis and localization of breast and soft tissue tumors,” said Martha G. Aronson, Merit’s President and Chief Executive Officer. “Merit has built a market leadership position in wire-free, non-radioactive breast localization procedures. This leadership is built upon our SCOUT platform, which utilizes the precision and accuracy of radar. View Point’s unique ultrasound-enhanced technology offers a highly innovative solution to localize more lesions at the time of biopsy – representing an estimated 1.3 million procedures annually in the United States alone. We look forward to discussing this acquisition in further detail on our first quarter investor conference call.” Merit’s first quarter investor call is scheduled for April 30, 2026.
The OneMark System is US Food and Drug Administration (FDA) cleared for its intended use and consists of a surgical detection console and ultrasound-enhanced tissue markers. After placement, the tissue markers are designed to be visible across commonly used imaging modalities and engineered to minimize interference with imaging studies. The combination of SCOUT and OneMark provides physicians with localization options during the initial diagnostic biopsy, and could reduce the need for a separate procedure to mark the location of tumors prior to surgery.
“The acquisition of View Point reinforces Merit’s mission to help reduce the burden that breast cancer places on patients and their loved ones,” said Adam Smith, Merit’s Chief Commercial Officer. “As treatment protocols evolve, the suspicious area is often most visible at the time of biopsy. Localizing these areas early in a patient’s cancer journey can help physicians plan treatment and may help reduce the need for additional localization procedures.”
Related Articles
-
Exclusive agreement expands Medtronic's comprehensive pain interventions portfolio, increases treatment options for patients living with chronic pain.
-
Asset acquisition expected to expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders.
-
RadNet leadership says the acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation.
-
Recor Medical Announces Paradise Ultrasound Renal Denervation System Receives Manufacturing and Marketing Approval in Japan for the Treatment of Resistant Hypertension.